Core Binding Factor Acute Myeloid Leukemia

Seminars in Oncology

Volumn 35, Issue 4, 2008, Pages 410-417

  Paschka, Peter ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CORE BINDING FACTOR; CORE BINDING FACTOR BETA; CYTARABINE; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CLINICAL FEATURE; CYTOGENETICS; DIAGNOSTIC TEST; DRUG MEGADOSE; GENE DELETION; GENE FUSION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HEMATOPOIESIS; HUMAN; KIT GENE; LEUKOCYTE COUNT; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; MUTATOR GENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

CHROMOSOMES, HUMAN, PAIR 16; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; CORE BINDING FACTORS; HUMANS; INVERSION, CHROMOSOME; LEUKEMIA, MYELOID, ACUTE; NEOPLASM, RESIDUAL; PROGNOSIS; TRANSLOCATION, GENETIC;

EID: 48749121814     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2008.04.011     Document Type: Article

References (76)

1. Rowley J.D. Identificaton of a translocation with quinacrine fluorescence in a patient with acute leukemia. Ann Genet 16 (1973) 109-112
2. Arthur D.C., and Bloomfield C.D. Association of partial deletion of the long arm of chromosome 16 and bone marrow eosinophilia in acute non-lymphocytic leukemia. Blood 62 (1983) 931
3. Bloomfield C.D., and Arthur D.C. Evaluation of leukemic cell chromosomes as a guide to therapy. Blood Cells 8 (1982) 501-518
4. Le Beau M.M., Larson R.A., Bitter M.A., Vardiman J.W., Golomb H.M., and Rowley J.D. Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. A unique cytogenetic-clinicopathological association. N Engl J Med 309 (1983) 630-636
5. Byrd J.C., Mrozek K., Dodge R.K., Carroll A.J., Edwards C.G., Arthur D.C., et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100 (2002) 4325-4336
6. Erickson P., Gao J., Chang K.S., Look T., Whisenant E., Raimondi S., et al. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood 80 (1992) 1825-1831
7. Liu P., Tarle S.A., Hajra A., Claxton D.F., Marlton P., Freedman M., et al. Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science 261 (1993) 1041-1044
8. Shurtleff S.A., Meyers S., Hiebert S.W., Raimondi S.C., Head D.R., Willman C.L., et al. Heterogeneity in CBF beta/MYH11 fusion messages encoded by the inv(16)(p13q22) and the t(16;16)(p13;q22) in acute myelogenous leukemia. Blood 85 (1995) 3695-3703
9. Speck N.A., and Gilliland D.G. Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer 2 (2002) 502-513
10. Downing J.R. The core-binding factor leukemias: lessons learned from murine models. Curr Opin Genet Dev 13 (2003) 48-54
11. van Dongen J.J., Macintyre E.A., Gabert J.A., Delabesse E., Rossi V., et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 13 (1999) 1901-1928
12. Castilla L.H., Garrett L., Adya N., Orlic D., Dutra A., Anderson S., et al. The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia. Nat Genet 23 (1999) 144-146
13. Yuan Y., Zhou L., Miyamoto T., Iwasaki H., Harakawa N., Hetherington C.J., et al. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci U S A 98 (2001) 10398-10403
14. Higuchi M., O'Brien D., Kumaravelu P., Lenny N., Yeoh E.J., and Downing J.R. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell 1 (2002) 63-74
15. Gilliland DG, Jordan CT, Felix CA. The molecular basis of leukemia. Hematology Am Soc Hematol Educ Program. 2004:80-97.
16. Peterson L.F., and Zhang D.E. The 8;21 translocation in leukemogenesis. Oncogene 23 (2004) 4255-4262
17. Yamagata T., Maki K., and Mitani K. Runx1/AML1 in normal and abnormal hematopoiesis. Int J Hematol 82 (2005) 1-8
18. Gelmetti V., Zhang J., Fanelli M., Minucci S., Pelicci P.G., and Lazar M.A. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 18 (1998) 7185-7191
19. Lutterbach B., Westendorf J.J., Linggi B., Patten A., Moniwa M., Davie J.R., et al. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol 18 (1998) 7176-7184
20. Wang J., Hoshino T., Redner R.L., Kajigaya S., and Liu J.M. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci U S A 95 (1998) 10860-10865
21. Liu S., Shen T., Huynh L., Klisovic M.I., Rush L.J., Ford J.L., et al. Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. Cancer Res 65 (2005) 1277-1284
22. Klisovic M.I., Maghraby E.A., Parthun M.R., Guimond M., Sklenar A.R., Whitman S.P., et al. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. Leukemia 17 (2003) 350-358
23. Liu S., Klisovic R.B., Vukosavljevic T., Yu J., Paschka P., Huynh L., et al. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells. J Pharmacol Exp Ther 321 (2007) 953-960
24. Fazi F., Racanicchi S., Zardo G., Starnes L.M., Mancini M., Travaglini L., et al. Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein. Cancer Cell 12 (2007) 457-466
25. Pabst T., Mueller B.U., Harakawa N., Schoch C., Haferlach T., Behre G., et al. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med 7 (2001) 444-451
26. Helbling D., Mueller B.U., Timchenko N.A., Schardt J., Eyer M., Betts D.R., et al. CBFB-SMMHC is correlated with increased calreticulin expression and suppresses the granulocytic differentiation factor CEBPA in AML with inv(16). Blood 106 (2005) 1369-1375
27. Mueller B.U., and Pabst T. C/EBPalpha and the pathophysiology of acute myeloid leukemia. Curr Opin Hematol 13 (2006) 7-14
28. Fazi F., Rosa A., Fatica A., Gelmetti V., De Marchis M.L., Nervi C., et al. A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. Cell 123 (2005) 819-831
29. Marcucci G., Mrozek K., Ruppert A.S., Maharry K., Kolitz J.E., Moore J.O., et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol 23 (2005) 5705-5717
30. Appelbaum F.R., Kopecky K.J., Tallman M.S., Slovak M.L., Gundacker H.M., Kim H.T., et al. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol 135 (2006) 165-173
31. Schlenk R.F., Benner A., Krauter J., Buchner T., Sauerland C., Ehninger G., et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 22 (2004) 3741-3750
32. Delaunay J., Vey N., Leblanc T., Fenaux P., Rigal-Huguet F., Witz F., et al. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. Blood 102 (2003) 462-469
33. Harrison C.J., Radford-Weiss I., Ross F., Rack K., le Guyader G., Vekemans M., et al. Fluorescence in situ hybridization analysis of masked (8;21)(q22;q22) translocations. Cancer Genet Cytogenet 112 (1999) 15-20
34. Hernandez J.M., Gonzalez M.B., Granada I., Gutierrez N., Chillon C., Ramos F., et al. Detection of inv(16) and t(16;16) by fluorescence in situ hybridization in acute myeloid leukemia M4Eo. Haematologica 85 (2000) 481-485
35. Mitterbauer M., Laczika K., Novak M., Mitterbauer G., Hilgarth B., Pirc-Danoewinata H., et al. High concordance of karyotype analysis and RT-PCR for CBF beta/MYH11 in unselected patients with acute myeloid leukemia. A single center study. Am J Clin Pathol 113 (2000) 406-410
36. Pirc-Danoewinata H., Dauwerse H.G., Konig M., Chudoba I., Mitterbauer M., Jager U., et al. CBFB/MYH11 fusion in a patient with AML-M4Eo and cytogenetically normal chromosomes 16. Genes Chromosomes Cancer 29 (2000) 186-191
37. Mrozek K., Prior T.W., Edwards C., Marcucci G., Carroll A.J., Snyder P.J., et al. Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol 19 (2001) 2482-2492
38. Bloomfield C.D., Lawrence D., Byrd J.C., Carroll A., Pettenati M.J., Tantravahi R., et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58 (1998) 4173-4179
39. Byrd J.C., Dodge R.K., Carroll A., Baer M.R., Edwards C., Stamberg J., et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 17 (1999) 3767-3775
40. Byrd J.C., Ruppert A.S., Mrozek K., Carroll A.J., Edwards C.G., Arthur D.C., et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol 22 (2004) 1087-1094
41. Schoch C., Haase D., Haferlach T., Gudat H., Buchner T., Freund M., et al. Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor. Leukemia 10 (1996) 1288-1295
42. Cairoli R., Beghini A., Grillo G., Nadali G., Elice F., Ripamonti C.B., et al. Prognostic impact of c-KIT mutations in core binding factor leukemias. an Italian retrospective study. Blood 107 (2006) 3463-3468
43. Care R.S., Valk P.J., Goodeve A.C., Abu-Duhier F.M., Geertsma-Kleinekoort W.M., Wilson G.A., et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol 121 (2003) 775-777
44. Schnittger S., Kohl T.M., Haferlach T., Kern W., Hiddemann W., Spiekermann K., et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 107 (2006) 1791-1799
45. Paschka P., Marcucci G., Ruppert A.S., Mrozek K., Chen H., Kittles R.A., et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 24 (2006) 3904-3911
46. Shimada A., Taki T., Tabuchi K., Tawa A., Horibe K., Tsuchida M., et al. KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. Blood 107 (2006) 1806-1809
47. Roskoski Jr. R. Signaling by Kit protein-tyrosine kinase-the stem cell factor receptor. Biochem Biophys Res Commun 337 (2005) 1-13
48. Shih L.Y., Liang D.C., Huang C.F., Chang Y.T., Lai C.L., Lin T.H., et al. Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples. Leukemia 22 (2008) 303-307
49. Boissel N., Leroy H., Brethon B., Philippe N., de Botton S., Auvrignon A., et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 20 (2006) 965-970
50. Wang Y.Y., Zhou G.B., Yin T., Chen B., Shi J.Y., Liang W.X., et al. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci U S A 102 (2005) 1104-1109
51. Nanri T., Matsuno N., Kawakita T., Suzushima H., Kawano F., Mitsuya H., et al. Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22). Leukemia 19 (2005) 1361-1366
52. Lennartsson J., Jelacic T., Linnekin D., and Shivakrupa R. Normal and oncogenic forms of the receptor tyrosine kinase kit. Stem Cells 23 (2005) 16-43
53. Cammenga J., Horn S., Bergholz U., Sommer G., Besmer P., Fiedler W., et al. Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate. Blood 106 (2005) 3958-3961
54. Kohl T.M., Schnittger S., Ellwart J.W., Hiddemann W., and Spiekermann K. KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor. Blood 105 (2005) 3319-3321
55. Goemans B.F., Zwaan C.M., Miller M., Zimmermann M., Harlow A., Meshinchi S., et al. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 19 (2005) 1536-1542
56. Beghini A., Bellini M., Magnani I., Colapietro P., Cairoli R., Morra E., et al. STI 571 inhibition effect on KITAsn822Lys-mediated signal transduction cascade. Exp Hematol 33 (2005) 682-688
57. Frost M.J., Ferrao P.T., Hughes T.P., and Ashman L.K. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 1 (2002) 1115-1124
58. Schittenhelm M.M., Shiraga S., Schroeder A., Corbin A.S., Griffith D., Lee F.Y., et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 66 (2006) 473-481
59. Growney J.D., Clark J.J., Adelsperger J., Stone R., Fabbro D., Griffin J.D., et al. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 106 (2005) 721-724
60. Gleixner K.V., Mayerhofer M., Aichberger K.J., Derdak S., Sonneck K., Bohm A., et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 107 (2006) 752-759
61. Bullinger L., Dohner K., Bair E., Frohling S., Schlenk R.F., Tibshirani R., et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 350 (2004) 1605-1616
62. Debernardi S., Lillington D.M., Chaplin T., Tomlinson S., Amess J., Rohatiner A., et al. Genome-wide analysis of acute myeloid leukemia with normal karyotype reveals a unique pattern of homeobox gene expression distinct from those with translocation-mediated fusion events. Genes Chromosomes Cancer 37 (2003) 149-158
63. Haferlach T., Kohlmann A., Schnittger S., Dugas M., Hiddemann W., Kern W., et al. Global approach to the diagnosis of leukemia using gene expression profiling. Blood 106 (2005) 1189-1198
64. Schoch C., Kohlmann A., Schnittger S., Brors B., Dugas M., Mergenthaler S., et al. Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. Proc Natl Acad Sci U S A 99 (2002) 10008-10013
65. Valk P.J., Verhaak R.G., Beijen M.A., Erpelinck C.A., Barjesteh van Waalwijk van Doorn-Khosrovani S., Boer J.M., et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350 (2004) 1617-1628
66. Ross M.E., Mahfouz R., Onciu M., Liu H.C., Zhou X., Song G., et al. Gene expression profiling of pediatric acute myelogenous leukemia. Blood 104 (2004) 3679-3687
67. Bullinger L., Rucker F.G., Kurz S., Du J., Scholl C., Sander S., et al. Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia. Blood 110 (2007) 1291-1300
68. Paschka P., Radmacher M.D., Marcucci G., Ruppert A.S., Vukosavljevic T., Whitman S.P., et al. Outcome prediction in adult core binding factor (CBF) acute myeloid leukemia (AML) with gene expression profiling: a Cancer and Leukemia Group B (CALGB) study [abstract 7011]. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25 Suppl (2007) 359s
69. Algar E. A review of the Wilms' tumor 1 gene (WT1) and its role in hematopoiesis and leukemia. J Hematother Stem Cell Res 11 (2002) 589-599
70. Nishida S., Hosen N., Shirakata T., Kanato K., Yanagihara M., Nakatsuka S., et al. AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1. Blood 107 (2006) 3303-3312
71. Yamagami T., Sugiyama H., Inoue K., Ogawa H., Tatekawa T., Hirata M., et al. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood 87 (1996) 2878-2884
72. Greiner J., Dohner H., and Schmitt M. Cancer vaccines for patients with acute myeloid leukemia-definition of leukemia-associated antigens and current clinical protocols targeting these antigens. Haematologica 91 (2006) 1653-1661
73. Rosenfeld C., Cheever M.A., and Gaiger A. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia 17 (2003) 1301-1312
74. Mailander V., Scheibenbogen C., Thiel E., Letsch A., Blau I.W., and Keilholz U. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 18 (2004) 165-166
75. Marcucci G., Caligiuri M.A., and Bloomfield C.D. Core binding factor (CBF) acute myeloid leukemia: is molecular monitoring by RT-PCR useful clinically?. Eur J Haematol 71 (2003) 143-154
76. Miyamoto T., Weissman I.L., and Akashi K. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc Natl Acad Sci U S A 97 (2000) 7521-7526